FDA Panel to Review Grail's Galleri Cancer Detection Test
An FDA advisory panel is set to evaluate Grail's multi-cancer early detection test, Galleri, amid broader shifts in biotech innovation and radiopharmaceuticals.
An FDA advisory panel is set to evaluate Grail's multi-cancer early detection test, Galleri, amid broader shifts in biotech innovation and radiopharmaceuticals.